STOCK TITAN

Neumora (NMRA) director and 10% owner receives 80,000 stock options at $1.86

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. director and 10% owner Kristina Burow received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.86 per share and expire on May 26, 2036.

According to the grant terms, 100% of the shares subject to the option vest on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting following that date. After this grant, the filing shows 80,000 derivative securities held directly.

Positive

  • None.

Negative

  • None.
Insider Burow Kristina
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 80,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 80,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 80,000 options Stock Option (Right to Buy) grant to director and 10% owner
Exercise price $1.86 per share Conversion or exercise price for the stock options
Expiration date May 26, 2036 Option term end date for the granted stock options
Underlying shares 80,000 shares Common stock underlying the granted stock options
Holdings after grant 80,000 derivative securities Total options held directly after the transaction
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.8600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares subject to the option vest on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Annual Meeting financial
"immediately prior to the next Annual Meeting following May 27, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burow Kristina

(Last)(First)(Middle)
8755 W. HIGGINS ROAD, SUITE 1025

(Street)
CHICAGO ILLINOIS 60631

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.8605/27/2026A80,000 (1)05/26/2036Common Stock80,000$080,000D
Explanation of Responses:
1. 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.
/s/ Michael Milligan, as Attorney-in-Fact for Kristina M. Burow05/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neumora Therapeutics (NMRA) report for Kristina Burow?

Neumora reported that director and 10% owner Kristina Burow received a grant of stock options for 80,000 shares of common stock. These options are a compensation-related award, not an open-market purchase or sale of existing shares.

What are the key terms of the 80,000 Neumora (NMRA) stock options granted to Kristina Burow?

The granted options cover 80,000 shares of Neumora common stock at an exercise price of $1.86 per share. They expire on May 26, 2036, giving a long exercise window typical for equity compensation.

When do Kristina Burow’s Neumora (NMRA) stock options vest?

All 80,000 options vest 100% on the earlier of the one-year anniversary of May 27, 2026 or immediately before the next annual meeting after that date. This creates a single vesting event rather than gradual vesting.

Is Kristina Burow’s Neumora (NMRA) Form 4 transaction a buy or a grant?

The Form 4 shows a grant/award acquisition, coded “A,” of stock options, not an open-market buy. The company awarded options with an exercise price of $1.86, so no cash changed hands at grant time.

How many Neumora (NMRA) derivative securities does Kristina Burow hold after this Form 4?

Following the reported transaction, the filing indicates that Kristina Burow directly holds 80,000 derivative securities in the form of stock options. These options are exercisable into an equal number of shares of Neumora common stock once vested.